Literature DB >> 6505717

Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites.

A Rahman, A Goodman, W Foo, J Harvey, F P Smith, P S Schein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6505717

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  5 in total

1.  Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity.

Authors:  R M Böhmer; K Hoffmann; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

3.  Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.

Authors:  Federico Pea; Domenico Russo; Mariagrazia Michieli; Daniela Damiani; Renato Fanin; Angela Michelutti; Teresa Michelutti; Stefano Piccolrovazzi; Michele Baccarani; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).

Authors:  K Lu; N Savaraj; J Kavanagh; L G Feun; M Burgess; G P Bodey; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

Authors:  K J O'Byrne; A L Thomas; R A Sharma; M DeCatris; F Shields; S Beare; W P Steward
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.